Overview
Description
Transcenta Holding Ltd. is a prominent biopharmaceutical company that focuses on the discovery and development of innovative therapeutics targeting critical diseases. As a public entity in the biotechnology sector, Transcenta is committed to advancing a pipeline of drug candidates that span various stages of clinical development, reflecting its strategic emphasis on addressing unmet medical needs in oncology and other significant therapeutic domains. The company integrates a comprehensive range of bioprocessing capabilities, from antibody discovery to cell line engineering and process development, underscoring its technical expertise and innovation-driven approach. Transcenta's operational model is also characterized by its robust R&D infrastructure, which supports collaborations with leading research institutions and industry partners, thereby reinforcing its market position as a forward-thinking entity in the rapidly evolving biopharma industry. Listed on the Hong Kong Stock Exchange, Transcenta plays a vital role in the global effort to deliver next-generation therapeutics, contributing significantly to the healthcare landscape through its commitment to scientific excellence and patient-centric solutions.
About
CEO
Dr. Xueming Qian Ph.D.
Employees
155
Address
B6-501, 218 Xinghu Street
Biobay
Suzhou, 215123, BC
China
Biobay
Suzhou, 215123, BC
China
Phone
86 12 6707 9200
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Hong Kong
MIC code
XHKG